Elariny, H.A.; Kabel, A.M.; Selim, H.M.R.M.; Helal, A.I.; Abdelrahman, D.; Borg, H.M.; Elkady, M.A.; Dawood, L.M.; El-Badawy, M.F.; Almalawi, H.F.A.;
et al. Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer’s Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling. Medicina 2024, 60, 1805.
https://doi.org/10.3390/medicina60111805
AMA Style
Elariny HA, Kabel AM, Selim HMRM, Helal AI, Abdelrahman D, Borg HM, Elkady MA, Dawood LM, El-Badawy MF, Almalawi HFA,
et al. Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer’s Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling. Medicina. 2024; 60(11):1805.
https://doi.org/10.3390/medicina60111805
Chicago/Turabian Style
Elariny, Hemat A., Ahmed M. Kabel, Heba Mohammed Refat M. Selim, Azza I. Helal, Doaa Abdelrahman, Hany M. Borg, Mennatallah A. Elkady, Lamees M. Dawood, Mohamed F. El-Badawy, Haifa Faisal A. Almalawi,
and et al. 2024. "Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer’s Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling" Medicina 60, no. 11: 1805.
https://doi.org/10.3390/medicina60111805
APA Style
Elariny, H. A., Kabel, A. M., Selim, H. M. R. M., Helal, A. I., Abdelrahman, D., Borg, H. M., Elkady, M. A., Dawood, L. M., El-Badawy, M. F., Almalawi, H. F. A., Arafa, E.-S. A., Alsufyani, S. E., & Arab, H. H.
(2024). Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer’s Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling. Medicina, 60(11), 1805.
https://doi.org/10.3390/medicina60111805
